Consolidation Of All Pradaxa Lawsuits
Today all Pradaxa lawsuits filed in federal district courts throughout the United States will be consolidated before Judge David Herndon in the Southern District of Illinois.In choosing Judge Herndon to preside over the Pradaxa litigation, the U.S. Judicial Panel on Multidistrict Litigation cited his handling of the Yaz and Yasmin litigation, also currently pending in the Southern District of Illinois.
Pradaxa lawyers filing new cases in federal district courts will have their cases automatically transferred to the Southern District of Illinois for pretrial proceedings.
Pradaxa was approved by the U.S. Food & Drug Administration (FDA) in October 2010 to prevent strokes in patients with an irregular heartbeat called non-vavular atrial fibrillation. While both Pradaxa and warfarin can cause internal bleeding, there are readily available antidotes for warfarin bleeding. The same can not be said for Pradaxa. Last year, Boehringer Ingelheim acknowledged that since March 2008, it had received 260 reports of bleeding-related deaths in patients taking Pradaxa
Plaintiffs involved in the Pradaxa lawsuits allege they suffered uncontrollable bleeding after taking the Boehringer Ingelheim anticoagulant drug. Boehringer Ingelheim is accused of failing to provide adequate warnings about the risk and the lack of a reversal agent to halt bleeding problems.
. In a report published this Spring, the Institute for Safe Medication Practices (ISMP) analyzed all adverse event reports submitted to the FDA during 2011 and found that there were 2,367 reports of bleeding problems with Pradaxa, and 542 reports of deaths among Pradaxa users.